Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(19):1461-1467; doi:10.1093/jnci/90.19.1461
© 1998 by Oxford University Press
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Decensi, A.
Right arrow Articles by Veronesi, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Decensi, A.
Right arrow Articles by Veronesi, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal Of The National Cancer Institute, Vol 90, 1461-1467, Copyright © 1998 by Oxford University Press

ARTICLES

Biologic activity of tamoxifen at low doses in healthy women

A Decensi, B Bonanni, A Guerrieri-Gonzaga, S Gandini, C Robertson, H Johansson, R Travaglini, MT Sandri, A Tessadrelli, G Farante, F Salinaro, D Bettega, A Barreca, P Boyle, A Costa and U Veronesi
Chemoprevention Unit, European Institute of Oncology, Milan, Italy. adecensi@ieo.it

BACKGROUND: Results of a clinical trial recently completed in the United States indicate that administration of tamoxifen (20 mg/day) to women at risk can reduce breast cancer incidence by approximately 50% but is associated with an increased risk of developing endometrial cancer and venous thromboembolic events. Since these adverse effects may be dose related, we investigated the effect of tamoxifen on several biomarkers when the drug was given at doses lower than those currently in use. METHODS: In two sequential experiments, 127 healthy hysterectomized women aged 35-70 years were randomly assigned to one of the following four treatment arms: placebo (n = 31) or tamoxifen at 20 mg/day (n = 30) (first experiment); or tamoxifen at 10 mg/day (n = 34) or tamoxifen at 10 mg/ alternate days (n = 32) (second experiment). Baseline and 2-month measurements of the following parameters were compared: 1) total cholesterol (primary end point) and other surrogate markers of cardiovascular disease, e.g., low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and lipoprotein(a); 2) blood cell count; 3) fibrinogen; 4) antithrombin III; 5) osteocalcin; and, 6) in a subgroup of 103 women, insulin-like growth factor-I (IGF-I), a possible surrogate marker for breast cancer. RESULTS: After adjustment for the baseline values, there were reductions in circulating levels of total cholesterol and IGF-I of the same magnitude in all three tamoxifen treatment arms. A similar pattern was observed for most of the other parameters. In the placebo arm, fibrinogen level, which showed a decrease, was the only parameter exhibiting change. CONCLUSIONS: Up to a 75% reduction in the conventional dose of tamoxifen (i.e., 20 mg/day) does not affect the activity of the drug on a large number of biomarkers, most of which are surrogate markers of cardiovascular disease. This study was hypothesis generating, and larger studies are warranted to assess the efficacy of tamoxifen at low doses.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A. Decensi, C. Robertson, A. Guerrieri-Gonzaga, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, V. Galimberti, E. Cassano, et al.
Randomized Double-Blind 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women
J. Clin. Oncol., August 10, 2009; 27(23): 3749 - 3756.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Vrieling, M. A. Rookus, E. Kampman, J. M.G. Bonfrer, A. Bosma, A. Cats, J. van Doorn, C. M. Korse, B. J.M. Witteman, F. E. van Leeuwen, et al.
No Effect of Red Clover-Derived Isoflavone Intervention on the Insulin-Like Growth Factor System in Women at Increased Risk of Colorectal Cancer
Cancer Epidemiol. Biomarkers Prev., October 1, 2008; 17(10): 2585 - 2593.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Decensi, S. Gandini, D. Serrano, M. Cazzaniga, M. Pizzamiglio, F. Maffini, G. Pelosi, C. Daldoss, U. Omodei, H. Johansson, et al.
Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users
J. Clin. Oncol., September 20, 2007; 25(27): 4201 - 4209.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K.-C. Leung, J. Brce, N. Doyle, H. J. Lee, G. M. Leong, K. Sjogren, and K. K. Y. Ho
Regulation of Growth Hormone Signaling by Selective Estrogen Receptor Modulators Occurs through Suppression of Protein Tyrosine Phosphatases
Endocrinology, May 1, 2007; 148(5): 2417 - 2423.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
U. Veronesi, P. Maisonneuve, and A. Decensi
Tamoxifen: An Enduring Star
J Natl Cancer Inst, February 21, 2007; 99(4): 258 - 260.
[Full Text] [PDF]

Home page
 J. Nutr.Home page
A. Vrieling, M. A. Rookus, E. Kampman, J. M. G. Bonfrer, C. M. Korse, J. van Doorn, J. W. Lampe, A. Cats, B. J. M. Witteman, F. E. van Leeuwen, et al.
Isolated Isoflavones Do Not Affect the Circulating Insulin-Like Growth Factor System in Men at Increased Colorectal Cancer Risk
J. Nutr., February 1, 2007; 137(2): 379 - 383.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. D. Ryan and P. E. Goss
Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer
Oncologist, July 1, 2006; 11(7): 718 - 731.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Guerrieri-Gonzaga, C. Robertson, B. Bonanni, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, F. Formelli, M. Intra, et al.
Preliminary Results on Safety and Activity of a Randomized, Double-Blind, 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in Premenopausal Women
J. Clin. Oncol., January 1, 2006; 24(1): 129 - 135.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. W. Voskuil, A. Vrieling, L. J. van't Veer, E. Kampman, and M. A. Rookus
The Insulin-like Growth Factor System in Cancer Prevention: Potential of Dietary Intervention Strategies
Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 195 - 203.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. Ponzone, N. Biglia, and P. Sismondi
Re: Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine
J Natl Cancer Inst, June 2, 2004; 96(11): 883 - 884.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. R. Kisanga, J. Gjerde, A. Guerrieri-Gonzaga, F. Pigatto, A. Pesci-Feltri, C. Robertson, D. Serrano, G. Pelosi, A. Decensi, and E. A. Lien
Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial
Clin. Cancer Res., April 1, 2004; 10(7): 2336 - 2343.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. L. Sabichi, M.-F. Demierre, E. T. Hawk, C. E. Lerman, and S. M. Lippman
Frontiers in Cancer Prevention Research
Cancer Res., September 15, 2003; 63(18): 5649 - 5655.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. Wu and P. Brown
Is Low-Dose Tamoxifen Useful for the Treatment and Prevention of Breast Cancer?
J Natl Cancer Inst, June 4, 2003; 95(11): 766 - 767.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. Decensi, C. Robertson, G. Viale, F. Pigatto, H. Johansson, E. R. Kisanga, P. Veronesi, R. Torrisi, M. Cazzaniga, S. Mora, et al.
A Randomized Trial of Low-Dose Tamoxifen on Breast Cancer Proliferation and Blood Estrogenic Biomarkers
J Natl Cancer Inst, June 4, 2003; 95(11): 779 - 790.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
K. F. Adams, K. M. Newton, C. Chen, S. S. Emerson, J. D. Potter, E. White, and J. W. Lampe
Soy Isoflavones Do Not Modulate Circulating Insulin-Like Growth Factor Concentrations in an Older Population in an Intervention Trial
J. Nutr., May 1, 2003; 133(5): 1316 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. H. Partridge, P. S. Wang, E. P. Winer, and J. Avorn
Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer
J. Clin. Oncol., February 15, 2003; 21(4): 602 - 606.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. Guerrieri-Gonzaga, L. Baglietto, H. Johansson, B. Bonanni, C. Robertson, M.-T. Sandri, L. Canigiula, C. Lampreda, S. Diani, E. A. Lien, et al.
Correlation between Tamoxifen Elimination and Biomarker Recovery in a Primary Prevention Trial
Cancer Epidemiol. Biomarkers Prev., September 1, 2001; 10(9): 967 - 970.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Schafer, E. S. Lee, R. M. O'Regan, K. Yao, and V. C. Jordan
Rapid Development of Tamoxifen-stimulated Mutant p53 Breast Tumors (T47D) in Athymic Mice
Clin. Cancer Res., November 1, 2000; 6(11): 4373 - 4380.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. B. Muchmore
Raloxifene: A Selective Estrogen Receptor Modulator (SERM) with Multiple Target System Effects
Oncologist, October 1, 2000; 5(5): 388 - 392.
[Abstract] [Full Text]

Home page
 JCOHome page
B. Conley, J. O’Shaughnessy, S. Prindiville, J. Lawrence, C. Chow, E. Jones, M. J. Merino, M. I. Kaiser-Kupfer, R. C. Caruso, M. Podgor, et al.
Pilot Trial of the Safety, Tolerability, and Retinoid Levels of N-(4-hydroxyphenyl) Retinamide in Combination With Tamoxifen in Patients at High Risk for Developing Invasive Breast Cancer
J. Clin. Oncol., January 14, 2000; 18(2): 275 - 275.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. L. Divi, M. R. Osborne, A. Hewer, D. H. Phillips, and M. C. Poirier
Tamoxifen-DNA Adduct Formation in Rat Liver Determined by Immunoassay and 32P-Postlabeling
Cancer Res., October 1, 1999; 59(19): 4829 - 4833.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Decensi, S. Gandini, A. Guerrieri-Gonzaga, H. Johansson, L. Manetti, B. Bonanni, M. T. Sandri, A. Barreca, A. Costa, C. Robertson, et al.
Effect of Blood Tamoxifen Concentrations on Surrogate Biomarkers in a Trial of Dose Reduction in Healthy Women
J. Clin. Oncol., September 1, 1999; 17(9): 2633 - 2633.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.